10 December 2018
Research conducted at Victoria University of Wellington and the Malaghan Institute of Medical Research has suggested a potential new way of treating glioblastoma, an aggressive form of brain cancer.
Nicole Jones, who graduates next week with her PhD, played a significant role in the work, which was led by Dr Melanie McConnell of the University’s School of Biological Sciences.
Nicole’s research suggests that suppressing a gene called BCL6 could help treat glioblastoma. Past research has shown BCL6 plays a significant role in many cancers, suppressing cancer cells and preventing them from growing, but newer research suggested BCL6 might play a different role in glioblastoma, Nicole says. Her PhD research aimed to investigate what role BCL6 played in glioblastoma.
“Throughout my PhD I completed extensive tests on the role of BCL6 in glioblastoma,” Nicole says. “My results seem to show that BCL6 has the opposite effect in glioblastoma cells than in other cancers. In glioblastoma, BCL6 seems to activate cancer cells and encourage them to grow. It also seems to connect to a very different part of the genome in glioblastoma than in other cancers.”
If BCL6 is responsible for activating glioblastoma cancer cells, suppressing the function of BCL6 could provide a possible new avenue for treating this cancer, Nicole says.
“The research team measured the effect that current BCL6-suppressing drugs have on glioblastoma cells, and the results were promising,” Nicole says. “These drugs, in combination with chemotherapy, do seem to kill off glioblastoma cells. If further tests support these results this would be an amazing leap forward for this field, because there has been very little change in treatment for people diagnosed with this terrible disease in the past 30 years.”
Dr McConnell’s research group will continue work in this area, confirming Nicole’s findings and looking at why BCL6 seems to have this effect on glioblastoma and how this effect might lead to new treatments.
Nicole’s goal was always to attend Victoria University of Wellington and study at the Malaghan Institute of Medical Research to help create cancer therapies. She first worked with Dr McConnell in her honours year before going on to PhD study.
“I always wanted to pursue cancer research, as I have had multiple family members affected by cancer,” Nicole says. “During my honours study I began work on glioblastoma, and luckily all the funding stars aligned and I could continue this project during my PhD. I hope to continue work on new cancer therapies throughout my career.”
This research was funded by the Cancer Research Trust of New Zealand and the Cancer Society of New Zealand.
Related articles
New Zealand to New York and back again: Malaghan researcher tackling liver cancer
18 November 2024
In Focus: CAR T-cell therapy, the battle of the blood cells
26 September 2024
Phase 2 clinical trial underway to confirm effectiveness and safety of NZ’s first CAR T-cell cancer therapy
23 July 2024
RNZ Our Changing World: Targeting bacteria, and health inequities
4 July 2024
New clinical research aims to reduce stomach cancer rates and disparities in New Zealand
28 May 2024
A revolution in cancer care is near; here’s what’s needed to make it happen
9 May 2024